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achieved a reliable model capable of producing severe reper-
fusion injury of the lungs similar to that seen in clinical lung
transplantation.
CONCLUSIONS
IR injury remains a substantial cause of morbidity and
mortality after lung transplantation. Novel methods to pro-
tect allografts during recovery will not only decrease the
incidence of PGD and chronic graft failure, but also may
embolden centers to use marginal donors with increased
ischemic times, thus increasing the currently limited donor
supply. In this study, we have examined the use of a long-
acting oral PDE inhibitor for donor preconditioning in
a model of IR injury. Our data demonstrate that this strategy
is effective for improving pulmonary performance and de-
creasing oxygen-derived free radical levels after reperfusion.
PDE enzymes and their downstream effectors may play
a critical role in reperfusion injury after lung transplantation.
We thank Mr Jeffrey Brawn, Mrs Melissa Jones, and Ms Tamara
Treat for their outstanding technical assistance. We acknowledge
Dr Irving L. Kron and associates at the University of Virginia for
providing guidance and expertise in setting up the ex vivo perfusion
apparatus at our institution.
References
1. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, et al.
Primary graft failure following lung transplantation. Chest. 1998;114:51-60.
2. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD,
et al. Reperfusion injury significantly impacts clinical outcome after pulmonary
transplantation. Ann Thorac Surg. 2000;69:1681-5.
3. Granton J. Update of early respiratory failure in the lung transplant recipient. Curr
Opin Crit Care. 2006;12:19-24.
4. Whitson BA, Prekker ME, Herrington CS, Whelan TP, Radosevich DM,
Hertz MI, et al. Primary graft dysfunction and long-term pulmonary function after
lung transplantation. J Heart Lung Transplant. 2007;26:1004-11.
5. Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM,
et al. Risk factors for primary graft dysfunction after lung transplantation. J
Thorac Cardiovasc Surg. 2006;131:73-80.
6. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion–induced
lung injury. Am J Respir Crit Care Med. 2003;167:490-511.
7. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, et al.
Impact of immediate primary lung allograft dysfunction on bronchiolitis obliter-
ans syndrome. Am J Respir Crit Care Med. 2007;175:507-13.
8. Ng CS, Wan S, Arifi AA, Yim AP. Inflammatory response to pulmonary ische-
mia-reperfusion injury. Surg Today. 2006;36:205-14.
9. Vural KM, Oz MC. Endothelial adhesivity, pulmonary hemodynamics and nitric
oxide synthesis in ischemia–reperfusion. Eur J Cardiothorac Surg. 2000;18:
348-52.
10. Schutte H, Witzenrath M, Mayer K, Weissmann N, Schell A, Rosseau S, et al. The
PDE inhibitor zaprinast enhances NO-mediated protection against vascular leak-
age in reperfused lungs. Am J Physiol. 2000;279:L496-502.
11. Featherstone RL, Chambers DJ, Kelly FJ. Comparison of phosphodiesterase in-
hibitors of differing isoenzyme selectivity added to St. Thomas’ hospital cardio-
plegic solution used for hypothermic preservation of rat lungs. Am J Respir Crit
Care Med. 2000;162(3 Pt 1):850-6.
12. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regula-
tion of nitric oxide signaling. Cardiovasc Res. 2007;75:303-14.
13. Masson P, Lambert SM, Brown M, Shabsigh R. PDE-5 inhibitors: current status
and future trends. Urol Clin North Am. 2005;32:511-25, viii.
14. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res.
2002;14(Suppl. 1):S57-64.
15. Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, et al. Review of
time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhib-
itors in treatment of erectile dysfunction. Urology. 2006;68:689-96.
16. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-
induced pulmonary fibrosis and pulmonary hypertension through inhibition of
ROS generation and RhoA/Rho kinase activation. Am J Physiol. 2008;294:
L24-33.
17. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of ar-
ginase in the aged mouse penis impairs erectile function and decreases eNOS ac-
tivity: influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ
Physiol. 2007;292:H1340-51.
18. Tankersley CG, Champion HC, Takimoto E, Gabrielson KL, Bedja D, Misra V,
et al. Exposure to inhaled particulate matter impairs cardiac function in senescent
mice. Am J Physiol Regul Integr Comp Physiol. 2008;295:R252-63.
19. Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA,
Diwan BA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension
due to global impairment in nitric oxide bioavailability. Blood. 2007;109:
3088-98.
20. Eckenhoff RG, Dodia C, Tan Z, Fisher AB. Oxygen-dependent reperfusion injury
in the isolated rat lung. J Appl Physiol. 1992;72:1454-60.
21. Korom S, Hillinger S, Cardell M, Zhai W, Tan Q, Dutly A, et al. Sildenafil extends
survival and graft function in a large animal lung transplantation model. Eur J
Cardiothorac Surg. 2006;29:288-93.
22. Pizanis N, Milekhin V, Tsagakis K, Aleksic I, Kamler M, Jakob H. PDE-5 inhib-
itor donor intravenous preconditioning is superior to supplementation in standard
preservation solution in experimental lung transplantation. Eur J Cardiothorac
Surg. 2007;32:42-7.
23. Dutly AE, Inci I, Hillinger S, Zalunardo M, Gaspert A, Rousson V, et al. Normal
gas exchange after 30-h ischemia and treatment with phosphodiesterase inhibitor
PDI747. Eur J Cardiothorac Surg. 2003;24:594-600.
24. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmaco-
logical preconditioning with sildenafil: basic mechanisms and clinical implica-
tions. Vasc Pharmacol. 2005;42:219-32.
25. Kukreja RC, Xi L. eNOS phosphorylation: a pivotal molecular switch in vasodi-
lation and cardioprotection? J Mol Cell Cardiol. 2007;42:280-2.
26. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO
synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007;42:
271-9.
27. Kukreja RC. Cardiovascular protection with sildenafil following chronic inhibi-
tion of nitric oxide synthase. Br J Pharmacol. 2007;150:538-40.
28. Cardella JA, Keshavjee SH, Bai XH, Yeoh JS, Granton JT, Meade MO, et al. In-
creased expression of nitric oxide synthase in human lung transplants after nitric
oxide inhalation. Transplantation. 2004;77:886-90.
29. Liu M, Tremblay L, Cassivi SD, Bai XH, Mourgeon E, Pierre AF, et al. Alter-
ations of nitric oxide synthase expression and activity during rat lung transplanta-
tion. Am J Physiol. 2000;278:L1071-81.
30. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, et al. The nitric
oxide/cyclic GMP pathway in organ transplantation: critical role in successful
lung preservation. Proc Natl Acad Sci U S A. 1994;91:12086-90.
Cardiothoracic Transplantation Weiss et al
1256 The Journal of Thoracic and Cardiovascular S
T
XDiscussion
Dr Christine L. Lau (Charlottesville, Va). My congratulations
to Dr Weiss and the Johns Hopkins group for another outstanding
presentation in the area of lung transplantation.
IR injury remains a major morbidity and potential mortality early
after lung transplantation, and, importantly, now it is known to be
a major risk factor for the development of bronchiolitis obliterans.
In this current study, the authors show in an experimental ex vivo
lung transplant model that oral preconditioning of the donor with
a PDE inhibitor leads to a decrease in IR injury, as evidenced by
markers of PaO2, PAP, and ROS. As pointed out, however, the con-
cept of PDE inhibitors to limit IR injury is not entirely new. Others
have shown similar benefits in the treatment of IR to those de-
scribed in this study with the use of intravenous sildenafil as well
as with other PDE inhibitors, specifically PDE-4 inhibitors. This
current study, however, does add to the previous investigationsurgery c May 2009
Weiss et al Cardiothoracic Transplantationby looking at an oral long-acting agent and thus has some obvious
advantages.
I have two questions. As you know, the primary effect of PDE-5
activity is on cyclic GMP levels and, in turn, stimulation of PKG.
Cyclic GMP also can influence other PDEs that in turn regulate cy-
clic adenosine monophosphate and, thus, lung function. Do you
plan to evaluate the synergy with other cyclic nucleotide PDEs,
for example, PDE-4 inhibition? Second, what are your plans for fu-
ture studies? Do you plan to look at leukocyte trafficking and plate-
let function, histology, and immunohistochemistry, and do you
plan any clinical trials?
Dr Weiss. Thank you, Dr Lau, for your critique and for your
questions and comments.
You bring up an excellent point regarding PDE-4. Certainly
others, including excellent work from the investigators at the
University of Virginia, have looked at activation of the PDE-4
enzyme in models of IR injury. To contrast the difference
between PDE-4 and PDE-5, PDE-4 breaks down cyclic adeno-
sine and PDE-5 breaks down cyclic GMP; PDE-4 is generally
found in inflammatory cells whereas PDE-5 is generally located
in endothelial cells. Although these are generalizations, thinking
about the enzymes in that manner can help us understand their
principal activity. We do not know to what extent tadalafil acts
on PDE-4. I suspect that there is some synergy, and we do
plan to investigate that aspect in future experiments. The answer
to your question is yes. I think that this brings up an opportunity
for dual therapy with both PDE-5 and PDE-4 inhibitors. We
would be interested in exploring that.The Journal of Thoracic and CIn terms of our future directions, we want to make our model
more clinically applicable. For example, we are interested in exam-
ining brain death in our model and we are interested in examining
the effect in a long-term survival model. There is some indication
from our data that the effect may be short-lived, and so we need
to focus on dosing and redosing as well. We are also interested in
looking at platelet function. Finally, we want to examine the role
of PDE enzymes in human lung tissue. We have an approved pro-
tocol at our institution to examine human lung tissue after reperfu-
sion that would have otherwise been discarded. These are some of
the future directions that we are interested in exploring.
Dr Yolonda L. Colson (Boston, Mass). Is most of this effect just
owing to changes in platelet function with your perfusion with the
drug on board, and do you have a control to control for changes in
platelet function?
Dr Weiss. Thank you, Dr Colson, for that question. Although we
know that PDE inhibition can affect platelet function, it is not likely
in our model inasmuch as we are pretreating the donor. We flush
out most of the blood during recovery and it is therefore unlikely
that recipient platelets are exposed to the drug.
Dr. Colson. You could argue that the PDE is just changing plate-
let function, and if you are not having microemboli, your PAP is
lower and your oxygenation is higher.
Dr Weiss. That is true. We did not measure recipient serum
levels of PDE inhibition to prove that the platelets are unaffected.
I think your point is well taken and may be a good reason to give
PDE inhibitors to recipients before transplantation, to decrease
injurious platelet behavior.ardiovascular Surgery c Volume 137, Number 5 1257
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